From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Parameter | Adjusted risk ratio | 95% CI |
---|---|---|
Drug therapy | ||
Non-TNF biologics ± DMARDs | Reference | – |
DMARDs | 0.58 | 0.51–0.66 |
TNFi ± DMARDs | 0.94 | 0.86–1.03 |
Tofacitinib ± DMARDs | 0.75 | 0.42–1.34 |
Sex (female) | 0.94 | 0.87–1.02 |
Age | 1.01 | 1.00–1.01 |
Year of cohort entry | ||
2011 | Reference | – |
2012 | 0.87 | 0.8–0.95 |
2013 | 1.00 | 0.91–1.1 |
Oral glucocorticoid use 1 year prior to cohort entry | ||
No use | Reference | – |
Use of ≤ 7.5 mg/day of prednisone equivalent dose | 0.94 | 0.88–1.02 |
Use of > 7.5 mg/day of prednisone equivalent dose | 1.07 | 0.90–1.26 |
Nonsteroidal anti-inflammatory drug use 1 year prior to cohort entry | 0.94 | 0.88–1.01 |
Selective COX-2 inhibitors use 1 year prior to cohort entry | 0.98 | 0.88–1.08 |
Charlson comorbidity index 1 year prior to cohort entry | 0.91 | 0.86–0.95 |
Infection-related hospitalization 1 year prior to cohort entry | 0.84 | 0.60–1.19 |
Number of emergency department visits 1 year prior to cohort entry | 0.96 | 0.90–1.01 |
Number of physician visits 1 year prior to cohort entry | 1.00 | 0.99–1.00 |
Number of rheumatology visits 1 year prior to cohort entry | 1.00 | 1.00–1.01 |
Number of hospitalizations 1 year prior to cohort entry | 0.97 | 0.89–1.06 |